19,910 Shares of Bristol Myers Squibb Company $BMY Purchased by White Pine Capital LLC

White Pine Capital LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the third quarter, HoldingsChannel reports. The firm purchased 19,910 shares of the biopharmaceutical company’s stock, valued at approximately $1,242,000.

Several other institutional investors also recently bought and sold shares of BMY. Financial Freedom LLC bought a new stake in Bristol Myers Squibb during the 3rd quarter valued at about $26,000. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $27,000. Addison Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $32,000. William Mack & Associates Inc. purchased a new stake in shares of Bristol Myers Squibb during the third quarter valued at approximately $35,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Bristol Myers Squibb by 68.2% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 577 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 234 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

BMY stock opened at $63.39 on Monday. The company has a market cap of $129.57 billion, a P/E ratio of 14.06, a price-to-earnings-growth ratio of 0.33 and a beta of 0.20. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The stock’s fifty day moving average price is $61.90 and its 200-day moving average price is $60.31.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.63 earnings per share. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BMY shares. Piper Sandler decreased their price objective on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Zacks Research downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.46.

Check Out Our Latest Report on BMY

Bristol Myers Squibb News Roundup

Here’s some of the latest news about BMY:

  • Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
  • Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
  • Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.